Literature DB >> 32011940

Five-Year Outcomes Among Medicaid-Enrolled Children With In Utero Opioid Exposure.

Marian P Jarlenski1, Elizabeth E Krans2, Joo Yeon Kim3, Julie M Donohue4, A Everette James5, David Kelley6, Bradley D Stein7, Debra L Bogen8.   

Abstract

The health of women and children affected by opioid use disorder is a priority for state Medicaid programs. Little is known about longer-term outcomes among Medicaid-enrolled children exposed to opioids in utero. We examined well-child visit use and diagnoses of pediatric complex chronic conditions in the first five years of life among children with opioid exposure, tobacco exposure, or neither exposure in utero. The sample consisted of 82,329 maternal-child dyads in the Pennsylvania Medicaid program in which the children were born in the period 2008-11 and followed up for five years. Children with in utero opioid exposure had a lower predicted probability of recommended well-child visit use at age fifteen months (42.1 percent) compared to those with tobacco exposure (54.1 percent) and those with neither exposure (55.7 percent). Children with in utero opioid exposure had a predicted probability of being diagnosed with a pediatric complex chronic condition similar to that among children with tobacco exposure and those with neither exposure (20.4 percent, 18.7 percent, and 20.2 percent, respectively). Our findings were consistent when we examined a subgroup of opioid-exposed children identified as having neonatal opioid withdrawal symptoms.

Entities:  

Keywords:  Abstinence; Access and use; Children's health; Chronic disease; Emergency departments; Health conditions; Health policy; Medicaid; Opioid use disorder; Pediatric chronic conditions; Pregnancy; Well-child visits

Mesh:

Substances:

Year:  2020        PMID: 32011940      PMCID: PMC7328447          DOI: 10.1377/hlthaff.2019.00740

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  30 in total

1.  Sociodemographic, insurance, and risk profiles of maternal smokers post the 1990s: how can we reach them?

Authors:  Kathleen E Adams; Cathy L Melvin; Cheryl L Raskind-Hood
Journal:  Nicotine Tob Res       Date:  2008-07       Impact factor: 4.244

Review 2.  Prenatal substance abuse: short- and long-term effects on the exposed fetus.

Authors:  Marylou Behnke; Vincent C Smith
Journal:  Pediatrics       Date:  2013-02-25       Impact factor: 7.124

3.  Spillover Effects of Adult Medicaid Expansions on Children's Use of Preventive Services.

Authors:  Maya Venkataramani; Craig Evan Pollack; Eric T Roberts
Journal:  Pediatrics       Date:  2017-11-13       Impact factor: 7.124

4.  Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment.

Authors:  Marcus A Bachhuber; Pooja K Mehta; Laura J Faherty; Brendan Saloner
Journal:  Med Care       Date:  2017-12       Impact factor: 2.983

5.  Estimating predicted probabilities from logistic regression: different methods correspond to different target populations.

Authors:  Clemma J Muller; Richard F MacLehose
Journal:  Int J Epidemiol       Date:  2014-03-05       Impact factor: 7.196

6.  Cigarette smoking in opioid-dependent pregnant women: neonatal and maternal outcomes.

Authors:  Hendrée E Jones; Sarah H Heil; Michelle Tuten; Margaret S Chisolm; Julianne M Foster; Kevin E O'Grady; Karol Kaltenbach
Journal:  Drug Alcohol Depend       Date:  2012-12-29       Impact factor: 4.492

7.  Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009.

Authors:  Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis
Journal:  JAMA       Date:  2012-04-30       Impact factor: 56.272

8.  Polysubstance Use Among US Women of Reproductive Age Who Use Opioids for Nonmedical Reasons.

Authors:  Marian Jarlenski; Colleen L Barry; Sarah Gollust; Amy J Graves; Alene Kennedy-Hendricks; Katy Kozhimannil
Journal:  Am J Public Health       Date:  2017-06-22       Impact factor: 9.308

Review 9.  Maternal Opioid Treatment: Human Experimental Research (MOTHER)--approach, issues and lessons learned.

Authors:  Hendrée E Jones; Gabriele Fischer; Sarah H Heil; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Kevin E O'Grady; Amelia M Arria
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

10.  Risk of preterm and early term birth by maternal drug use.

Authors:  Rebecca J Baer; Christina D Chambers; Kelli K Ryckman; Scott P Oltman; Larry Rand; Laura L Jelliffe-Pawlowski
Journal:  J Perinatol       Date:  2018-12-20       Impact factor: 2.521

View more
  4 in total

1.  Maternal opioid exposure, neonatal abstinence syndrome, and infant healthcare utilization: A retrospective cohort analysis.

Authors:  Jean Y Ko; Jangho Yoon; Van T Tong; Sarah C Haight; Roshni Patel; Karilynn M Rockhill; Jeff Luck; Carrie Shapiro-Mendoza
Journal:  Drug Alcohol Depend       Date:  2021-04-20       Impact factor: 4.852

2.  Healthcare Patterns of Pregnant Women and Children Affected by OUD in 9 State Medicaid Populations.

Authors:  Marian Jarlenski; Joo Yeon Kim; Katherine A Ahrens; Lindsay Allen; Anna Austin; Andrew J Barnes; Dushka Crane; Paul Lanier; Rachel Mauk; Shamis Mohamoud; Nathan Pauly; Jeffrey Talbert; Kara Zivin; Julie M Donohue
Journal:  J Addict Med       Date:  2021 Sep-Oct 01       Impact factor: 3.702

3.  Postpartum Treatment for Substance Use Disorder Among Mothers of Infants with Neonatal Abstinence Syndrome and Prenatal Substance Exposure.

Authors:  Laura J Faherty; Sara Heins; Ashley M Kranz; Bradley D Stein
Journal:  Womens Health Rep (New Rochelle)       Date:  2021-06-01

4.  Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study.

Authors:  Catherine A Chappell; Kimberly K Scarsi; Brian J Kirby; Vithika Suri; Anuj Gaggar; Debra L Bogen; Ingrid S Macio; Leslie A Meyn; Katherine E Bunge; Elizabeth E Krans; Sharon L Hillier
Journal:  Lancet Microbe       Date:  2020-07-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.